NOVN Novan Inc.

2.68
-0.07  -3%
Previous Close 2.75
Open 2.76
Price To Book -29.78
Market Cap 69,866,887
Shares 26,069,734
Volume 69,810
Short Ratio
Av. Daily Volume 587,389

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 data due 1Q 2020 or before.
SB206
Molluscum contagiosum skin infection
Phase 2 trial to be initiated 4Q 2019.
SB414
Atopic Dermatitis

Latest News

  1. Novan Expands External Business Partner Network
  2. Novan to Participate in JMP Securities Life Sciences Conference
  3. Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)
  4. First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program
  5. Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019
  6. Executive Voice: She raises cash, and hope, for struggling Novan
  7. Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
  8. With a fresh $30 million, Durham pharma set to expand drug pipeline
  9. Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
  10. Novan adds more cash, now confident it can execute
  11. Novan Completes Funding Transaction with Ligand Pharmaceuticals
  12. Novan Confirms Corporate Update Conference Call and Webcast
  13. Cash-starved Novan adds capital, but at a price
  14. Novan Secures Up to $35 Million in Non-Dilutive Funding
  15. Novan stock plummets as Durham company searches for additional financing
  16. Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
  17. Novan and Sato Advance Japan Market and Dermatology Partnership
  18. Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
  19. Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*